Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Preventing cross-contamination in multi-product facilities

30 Mar 2021 (Last Updated March 30th, 2021 17:44)

Sponsored by Baxter International Sponsored by Visit Company
Preventing cross-contamination in multi-product facilities

The potential for cross-contamination is always a concern when producing different drugs in a shared facility, especially when manufacturing oncology drugs that are highly potent substances with cytotoxic or genotoxic effects.

The development of targeted therapies based either on small molecules or monoclonal antibodies opened ground for rapid evolution and a large diversification in the clinical landscape. Recent market reports suggest an increase in niche products, making dedicated facilities less practical, which may lead to more outsourcing of drug production to contract manufacturing organisations with experience in handling different products in shared facilities can be an option.

How cross-contamination can be avoided

Following recalled contaminated products such as Cholestyramine Resin in 1998, the industry moved on from using “visibly clean” as a sole acceptance criterion, moving towards quantifiable criteria such as the 0.001 dose criterion, or the 3 or 10 ppm values. Although these dose-based values were widely accepted by the industry, none of these values made their way into official regulatory guidance documents. FDA always expected a scientifically justifiable basis for the establishment of limits.

This movement towards science-based limits began with the ISPE Risk-MaPP Baseline Guide with the definition of the Acceptable Daily Exposure. This is a conservative approach to define a daily dose of a substance, below which no adverse events are anticipated, even if exposure occurs for a lifetime. The EMA converted this idea into the first official guideline and established the Permitted Daily Exposure (PDE).

Baxter’s facility: setting a safety precedent

At Baxter’s oncology contract manufacturing facility in Halle, Germany, guidance to help prevent cross-contamination has been fully developed to allow manufacturers to assess risk and determine where control strategies are necessary to meet acceptable limits for cross-contamination. With over 60 years of oncology experience, patient safety and world-class manufacturing continue to be a top priority.

At Baxter’s oncology facility, risk assessment is combined with state-of-the-art organisational procedures and technical standards in accordance with current industry guidance. The goal is to help ensure the greatest possible reduction of different modes of potential cross-contamination

This means that Baxter’s oncology facility is capable of handling cytotoxic and non-cytotoxic small molecules, both in liposomal and nanoparticulate formulations, as well as monoclonal antibodies, ADCs and nucleic acid products.

With the advent of more product niches and often lowered production quantities, facilities that are experienced and versatile in handling cytotoxic, highly potent and non-cytotoxic oncology products can present a valid option when considering outsourcing. Risks for cross-contamination must be properly assessed, using state-of-the-art organisation procedures, technical standards and current industry guidance. As is the case in all areas of drug development, patient safety is the manufacturers key priority.

To learn more about how Baxter can help you mitigate risk of cross-contamination, download the free white paper below.

Free Whitepaper

Manufacturing of cytotoxic and non-cytotoxic drugs in a multi-product facility

The potential for cross-contamination is always a concern when producing different drugs in a shared facility, especially when manufacturing oncology drugs that are highly potent substances with cytotoxic or genotoxic effects.

Recent market reports suggest an increase in niche products, making dedicated facilities less practical, which may lead to more outsourcing of drug production to contract manufacturing organisations with experience in handling different products in
shared facilities can be an option.

To learn how Baxter International may be able to help you manage the production of these drugs, download the freewhitepaper below.

By clicking the “Submit” button above, you accept the Terms & Conditions and acknowledge that your data will be used as described in the Baxter Biopharma Solutions Privacy Policy.

We will also collect and use the information you provide for carefully considered and specific purposes, where we believe we have a legitimate interest in doing so, for example to send you communications about similar products and services we offer. We will always give you an option to opt out of any future communications from us. You can find out more about our legitimate interest activity in our privacy policy here. ‘We’ includes Verdict Media Limited and other GlobalData brands as detailed here.